Flint Animal Cancer Center

CHOP Dose Escalation for Canine Lymphoma

Patient Disease:

Canine Lymphoma 

Study Name:

CHOP Dose Escalation for Canine Lymphoma

Purposes of the study:

  • Assess the ability to successfully escalate drug doses in dogs with lymphoma treated with 15-week CHOP chemotherapy using a standardized dose escalation protocol

  • Evaluate effect of dose escalation on outcome in dogs with lymphoma

  • Assess toxicity associated with the protocol

 Primary Eligibility Criteria:

  • Dogs with newly diagnosed, multicentric lymphoma whose owners elect to treat with CHOP chemotherapy

  • No prior chemotherapy; cannot have received prednisone for more than 7 days prior to starting CHOP chemotherapy

  • Must have good function of liver and kidneys, and be free of severe underlying disease

Study Protocol:

  • Dogs will be treated with the first cycle of CHOP drugs at standard doses; blood samples will be collected for several hours after the first doses of each drug

  • Dose escalation will then be implemented for subsequent doses according to a standardized dose escalation protocol

  • Once a dog has had a dose reduction for a drug, no further dose escalation will be implemented for that drug

  • CBCs will be performed prior to each chemotherapy treatment as well as at the expected drug nadir after any dose adjustment

  • Lymph node biopsies will also be collected at various time points for study purposes

Owner Responsibilities:

  • To make and keep all appointments for the study protocol

 Financial Incentives:

  • Study will pay for the costs of exam fees associated with the trial as well as costs related to lymph node biopsies

  • A credit of $1000 will be given at the start of the trial in anticipation of the additional visits and diagnostics that will likely be required as part of this trial

  • The owner is responsible for costs of tests needed to confirm study eligibility as well as for all costs related to CHOP chemotherapy beyond the $1000 credit

 


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.